Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
Int J Cancer
; 153(12): 2032-2044, 2023 12 15.
Article
in En
| MEDLINE
| ID: mdl-37602928
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Int J Cancer
Year:
2023
Document type:
Article